Technical Analysis for IFRX - InflaRx N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -2.10% | |
| Crossed Above 20 DMA | Bullish | -2.10% | |
| MACD Bullish Signal Line Cross | Bullish | -2.10% | |
| Pocket Pivot | Bullish Swing Setup | -2.10% | |
| Gapped Up | Strength | -2.10% | |
| 20 DMA Resistance | Bearish | 12.00% | |
| Stochastic Buy Signal | Bullish | 12.00% | |
| Lower Bollinger Band Walk | Weakness | 12.00% |
| Alert | Time |
|---|---|
| Down 5% | about 18 hours ago |
| Down 3% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| Up 3% | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 06/05/2024
InflaRx N.V. Description
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Immune System Clinical Development Antibodies Autoimmune Disease Monoclonal Antibodies Monoclonal Antibody Inflammatory Diseases Complement System Hidradenitis Suppurativa C5a
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.78 |
| 52 Week Low | 1.14 |
| Average Volume | 199,037 |
| 200-Day Moving Average | 2.06 |
| 50-Day Moving Average | 1.46 |
| 20-Day Moving Average | 1.33 |
| 10-Day Moving Average | 1.30 |
| Average True Range | 0.13 |
| RSI (14) | 52.83 |
| ADX | 15.85 |
| +DI | 17.44 |
| -DI | 12.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.08 |
| Chandelier Exit (Short, 3 ATRs) | 1.57 |
| Upper Bollinger Bands | 1.48 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | 0.74 |
| BandWidth | 22.92 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0144 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.60 | ||||
| Resistance 3 (R3) | 1.60 | 1.54 | 1.56 | ||
| Resistance 2 (R2) | 1.54 | 1.49 | 1.54 | 1.55 | |
| Resistance 1 (R1) | 1.47 | 1.46 | 1.44 | 1.47 | 1.54 |
| Pivot Point | 1.41 | 1.41 | 1.40 | 1.41 | 1.41 |
| Support 1 (S1) | 1.34 | 1.36 | 1.31 | 1.34 | 1.26 |
| Support 2 (S2) | 1.28 | 1.33 | 1.28 | 1.25 | |
| Support 3 (S3) | 1.21 | 1.28 | 1.24 | ||
| Support 4 (S4) | 1.21 |
